Clinical trial · no report yet · Phase 3
PACIFIC-8
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT05211895 ↗
- Active, not recruiting
- AstraZeneca
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab Plus Domvanalimab(AB154) in Participants With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease Has Not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Durvalumab; Domvanalimab; Placebo
- Arms
- Arm A: Durvalumab + Domvanalimab · Experimental
- Arm B: Durvalumab + Placebo · Active comparator
- Enrollment
- 791
- Primary outcomes
- Progression Free Survival (PFS)
- Sponsor
- AstraZeneca with Arcus Biosciences, Inc.
- Start
- Feb 18, 2022
- Primary completion
- Aug 10, 2026
- Results posted
- No
- Registry record
- NCT05211895 · updated Aug 28, 2026